260 related articles for article (PubMed ID: 21133802)
1. The particle has landed--characterizing the fate of inhaled pharmaceuticals.
Patton JS; Brain JD; Davies LA; Fiegel J; Gumbleton M; Kim KJ; Sakagami M; Vanbever R; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S71-87. PubMed ID: 21133802
[TBL] [Abstract][Full Text] [Related]
2. The lungs as a portal of entry for systemic drug delivery.
Patton JS; Fishburn CS; Weers JG
Proc Am Thorac Soc; 2004; 1(4):338-44. PubMed ID: 16113455
[TBL] [Abstract][Full Text] [Related]
3. Assessment methods of inhaled aerosols: technical aspects and applications.
Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
[TBL] [Abstract][Full Text] [Related]
4. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
Sakagami M
Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary formulations: what remains to be done?
Weers JG; Bell J; Chan HK; Cipolla D; Dunbar C; Hickey AJ; Smith IJ
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S5-23. PubMed ID: 21133800
[TBL] [Abstract][Full Text] [Related]
6. Inhaling medicines: delivering drugs to the body through the lungs.
Patton JS; Byron PR
Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
[TBL] [Abstract][Full Text] [Related]
7. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
8. Respiratory epithelial penetration and clearance of particle-borne benzo[a]pyrene.
Gerde P; Muggenburg BA; Lundborg M; Tesfaigzi Y; Dahl AR
Res Rep Health Eff Inst; 2001 Apr; (101):5-25; discussion 27-32. PubMed ID: 11488545
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary drug delivery: medicines for inhalation.
Henning A; Hein S; Schneider M; Bur M; Lehr CM
Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
[TBL] [Abstract][Full Text] [Related]
10. Treating systemic diseases via the lung.
Sanjar S; Matthews J
J Aerosol Med; 2001; 14 Suppl 1():S51-8. PubMed ID: 11424894
[TBL] [Abstract][Full Text] [Related]
11. In vivo animal models for drug delivery across the lung mucosal barrier.
Cryan SA; Sivadas N; Garcia-Contreras L
Adv Drug Deliv Rev; 2007 Sep; 59(11):1133-51. PubMed ID: 17900750
[TBL] [Abstract][Full Text] [Related]
12. Clinical perspectives on pulmonary systemic and macromolecular delivery.
Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
[TBL] [Abstract][Full Text] [Related]
13. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection.
Schanker LS; Mitchell EW; Brown RA
Drug Metab Dispos; 1986; 14(1):79-88. PubMed ID: 2868870
[TBL] [Abstract][Full Text] [Related]
14. Inhaled nanoparticles--a current review.
Yang W; Peters JI; Williams RO
Int J Pharm; 2008 May; 356(1-2):239-47. PubMed ID: 18358652
[TBL] [Abstract][Full Text] [Related]
15. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles.
Oberdorster G
Inhal Toxicol; 1996; 8 Suppl():73-89. PubMed ID: 11542496
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo testing methods for respiratory drug delivery.
Agu RU; Ugwoke MI
Expert Opin Drug Deliv; 2011 Jan; 8(1):57-69. PubMed ID: 21174605
[TBL] [Abstract][Full Text] [Related]
17. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
[TBL] [Abstract][Full Text] [Related]
18. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
[TBL] [Abstract][Full Text] [Related]
19. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action.
Henkin RI
Nutrition; 2010 Jan; 26(1):33-9. PubMed ID: 20005465
[TBL] [Abstract][Full Text] [Related]
20. Challenges in inhaled product development and opportunities for open innovation.
Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
